Armstrong expects to utilize its
research and development capabilities, both internally
and through strategic alliances, to develop additional
products utilizing its proprietary delivery systems.
Armstrong’s Clinical Department performs clinical
research to demonstrate the safety, performance,
efficacy, and bioequivalence of its products.
Armstrong’s pipeline will
continue to build upon its substantial experience in the
development, manufacture and marketing (mainly in the
U.S.) of inhaled respiratory drugs, primarily for
bronchial asthma and chronic obstructive pulmonary
disease (COPD), delivered by metered-dose inhalers. At the core
of Armstrong’s efforts to grow its respiratory business
is a continued investment in manufacturing capacity both
for metered-dose inhalers and nasal sprays, which allow
Armstrong to play an important role in all major markets
where it operates.